• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Outlook Therapeutics Inc (NQ: OTLK )

    6.350 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Outlook Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 Next >
    OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    OTLK Stock Earnings: Outlook Therapeutics Beats EPS for Q3 2024
    OTLK stock results show that Outlook Therapeutics beat analyst estimates for earnings per share the third quarter of 2024. 
    Via InvestorPlace
    3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
    Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices. 
    Via MarketBeat
    3 Undervalued Gems Set to Soar 1,000% by 2026
    Discover the fundamentals behind three undervalued stocks to buy in the oil and gas, advertising, and biotechnology industries. 
    Via InvestorPlace
    MarketBeat Week in Review – 6/17 - 6/21
    Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally 
    Via MarketBeat
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
    Outlook Therapeutics (NASDAQ: OTLK) has gained attention, with analysts forecasting an upside of over 500% based on the consensus price target. 
    Via MarketBeat
    OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024
    OTLK stock results show that Outlook Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
    With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks. 
    Via InvestorPlace
    Insiders Buying Outlook Therapeutics And 2 Other Stocks
    Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades. 
    Via Benzinga
    Gold Moves Lower; Lululemon Shares Plummet
    U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.3% on Friday. The Dow traded down 0.49% to 39,585.67 while the NASDAQ rose 0.26% to 16,444.91. The S&P 500... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results. 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Dow Dips 200 Points; Nike Shares Fall After Q3 Results
    U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points. The Dow traded down 0.54% to 39,565.50 while the NASDAQ rose 0.04% to 16,408.74. The S&P 500 also... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?
    Outlook Therapeutics stock sees uptick as European Medicines Agency committee issues positive opinion on ONS-5010/LYTENAVA for wet age-related macular degeneration (wet AMD). Strong trading volume... 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Over $1.7M Bet On Globalstar? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
    The Dow Jones index closed higher by around 47 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    7 of the Best Speculative Stocks You Can Snag for Less Than $1
    Although speculative stocks under $1 are by their very nature extremely risky, these ideas might have enough to go the distance. 
    Via InvestorPlace
    7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
    Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    OTLK DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal Product Safety
    OTLK DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action – OTLK
    From The Rosen Law Firm, P.A.
    Via Business Wire
    OTLK IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal Product Safety
    OTLK DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
    From The Rosen Law Firm PA
    Via GlobeNewswire
    OTLK DEADLINE ALERT: ROSEN, A LEADING AND RANKED FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal Product Safety
    OUTLOOK DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Outlook Therapeutics, Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    OTLK DEADLINE ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal Product Safety
    Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.